Fujisawa Pharmaceutical Company, Ltd.

Harumi Yamazaki

Fumihiko Sakai

Yoshihiro Yokota

Nobuchika Yamamoto

Shigeru Johki

Osamu Nakayama

Takeshi Ishikawa

Noboru Chida

A new use of immunosuppressant for treating or preventing MMp-medicated diseases is provided. The preferred immunosuppresants are tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxyascomycin (pimecrolimus). Particularly, preferable MMP-mediated diseases are the diseases or conditions caused by gelatinase and/or collagenase, and/or inflammatory diseases concerned with gelatinase; such as arthritis (e.g., osteoarthritis, rheumatoid arthritis, etc.) cerebral diseases (e.g., stroke, etc.), tissue ulceration (e.g., corneal, epidermal and gastriculceration, etc.), abnormal wound healing, periodontal diseases, bone diseases (e.g., Paget's diseases, osteoporosis. etc.), tumor growth, tumor metastasis or invasion, HIV-infection, decubitus, decubitis ulcer, restenosis, epidermolysis bullosa, sepsis, septic shock, neoplasm, psoriasis, neovascularization and multiple sclerosis.

Use of immunosuppressants for MMP mediated diseases

Methods for increasing graft survival time comprising administering the combination of a compound that inhibits the production of nitric oxide and a compound that is a tricyclic macrolide, such as tacrolimus.

Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins

Growing community of inventors

Ibaraki, Japan

Harumi Yamazaki